Standard BioTools Inc.
LABNASDAQHealthcare● Active
$0.80
$-0.35(-30.23%)
Market Cap$313192335
P/E Ratio—
52W High$1.72
52W Low$0.8051
Standard BioTools Inc. (LAB) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LAB · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $85.33M | $174.43M | $106.34M | $97.95M | $130.58M |
| Cost of Revenue | $42.79M | $90.17M | $55.89M | $60.90M | $61.21M |
| Gross Profit | $42.54M | $84.26M | $50.45M | $37.05M | $69.37M |
| Gross Margin %(computed) | 49.86% | 48.31% | 47.44% | 37.83% | 53.13% |
| Operating Expenses | |||||
| R&D Expenses | $25.99M | $62.41M | $25.95M | $37.38M | $37.94M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $135.85M | $259.50M | $127.05M | $153.26M | $136.83M |
| Operating Income | ($93.31M) | ($175.24M) | ($76.60M) | ($116.20M) | ($67.46M) |
| Operating Margin %(computed) | -109.34% | -100.46% | -72.03% | -118.64% | -51.66% |
| Interest Income | $9.18M | $20.20M | $5.57M | $2.23M | $0.00M |
| Interest Expense | $0.03M | $3.32M | $4.57M | $4.33M | $3.82M |
| Income Before Tax | ($96.70M) | ($138.31M) | ($74.20M) | ($192.93M) | ($63.66M) |
| Income Tax Expense | ($37.88M) | $0.57M | $0.45M | ($2.83M) | ($4.42M) |
| Net Income | ($74.90M) | ($138.88M) | ($74.66M) | ($190.10M) | ($59.24M) |
| Net Margin %(computed) | -87.77% | -79.62% | -70.21% | -194.08% | -45.36% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.20 | $-0.52 | $-0.94 | $-2.43 | $-0.78 |
| Wtd Avg Shares | 381.62M | 352.67M | 79.16M | 78.31M | 75.79M |
| EBITDA | ($86.32M) | ($118.14M) | ($54.46M) | ($173.57M) | ($44.27M) |
| EBITDA Margin %(computed) | -101.16% | -67.73% | -51.21% | -177.21% | -33.90% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Standard BioTools Inc. data
About Standard BioTools Inc. (LAB) Income Statement
Standard BioTools Inc. (LAB) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, LAB reported revenue of $0.09B, gross profit of $0.04B (gross margin 49.86%), and net income of ($0.07B) — a net profit margin of -87.77%.
Frequently asked questions
LAB · 4 questionsStandard BioTools Inc. (LAB) reported revenue of $0.09B for 2025, down 51.1% year-over-year.
LAB revenueLAB salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08